{"doc_id": "si-2020-0698-reg-1", "parent_doc_id": "si-2020-0698", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription \n\nand Control of Supply) (Amendment) (No. 7) Regulations 2020. \n\n(2) The collective citation “the Medicinal Products (Prescription and \n\nControl of Supply) Regulations 2003 to 2020” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 7) regulation 2020 (2) collective citation medicinal product (prescription control supply) regulation 2003 2020 includes regulation", "start_char": 640, "end_char": 930, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-reg-2", "parent_doc_id": "si-2020-0698", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "2. In these Regulations “Principal Regulations” means the Medicinal", "text_raw": "2. In these Regulations “Principal Regulations” means the Medicinal \nProducts (Prescription and Control of Supply) Regulations 2003 (S.I. No. 540 \nof 2003).", "text_norm": "2 regulation principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003)", "start_char": 930, "end_char": 1089, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-reg-3", "parent_doc_id": "si-2020-0698", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "3. The Principal Regulations are amended by inserting after Regulation 4E", "text_raw": "3. The Principal Regulations are amended by inserting after Regulation 4E \n(inserted by Regulation 4 of the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 2) Regulations 2015 (S.I. No. 449 of 2015)) the \nfollowing Regulation: \n\n“Supply and administration of Covid-19 vaccinations and epinephrine \n(adrenaline) \n\n4F. It shall not be a contravention of a provision of these Regulations for \na person to supply another person with, and to administer to that person, a \nmedicinal product specified in column 1 of the Twelfth Schedule if, and \nonly if— \n\n(a) \n\nthe medicinal product is supplied and administered as part of the \nvaccination programme implemented in the State to address the \nCovid-19 emergency, \n\n(b) \n\nthe person supplying and administering the medicinal product \nis— \n\n(i) \n\na registered nurse (including a registered midwife), \n\n(ii) a registered pharmacist, \n\n(iii) an advanced paramedic, \n\n(iv) a paramedic, \n\n(v) \n\nan emergency medical technician, or \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 5th January, 2021. \n\n \n \n \n \n \n \n \n \n\f[698] 3 \n\n(vi) a person registered in the register of the Physiotherapists \nRegistration Board established under section 36(1)(a) of \nthe Health and Social Care Professionals Act 2005 (No. 27 \nof 2005), \n\nand has received training in the administration of the product, as \napproved by the regulatory body for the profession concerned, \n\n(c) \n\n(d) \n\nthe medicinal product is supplied and administered in a suitable \nand appropriate place, having regard to public convenience and \nthe need to protect the health and safety of the public and safely \nadminister the product, and \n\nthe product is administered in accordance with the requirements \nspecified in columns 2 to 5 of the Twelfth Schedule opposite the \nmention of the product specified in column 1 of that Schedule.”", "text_norm": "3 principal regulation amended inserting regulation 4e (inserted regulation 4 medicinal product (prescription control supply) (amendment) (no 2) regulation 2015 (s.i no 449 2015)) following regulation supply administration covid-19 vaccination epinephrine (adrenaline) 4f shall contravention provision regulation person supply another person administer person medicinal product specified column 1 twelfth schedule if-- (a) medicinal product supplied administered part vaccination programme implemented state address covid-19 emergency (b) person supplying administering medicinal product is-- (i) registered nurse (including registered midwife) (ii) registered pharmacist (iii) advanced paramedic (iv) paramedic (v) emergency medical technician notice making statutory instrument published iris oifigiuil 5th january 2021 698 3 (vi) person registered register physiotherapist registration board established section 36(1)(a) health social care professional act 2005 (no 27 2005) received training administration product approved regulatory body profession concerned (c) (d) medicinal product supplied administered suitable appropriate place regard public convenience need protect health safety public safely administer product product administered accordance requirement specified column 2 5 twelfth schedule opposite mention product specified column 1 schedule", "start_char": 1089, "end_char": 2986, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-reg-4", "parent_doc_id": "si-2020-0698", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "4. The Principal Regulations are amended by inserting after Regulation 10A", "text_raw": "4. The Principal Regulations are amended by inserting after Regulation 10A \n(inserted by Regulation 6 of the Medicinal Products (Prescription and Control \nof Supply) (Amendment) Regulations 2011 (S.I. No. 525 of 2011)) the \nfollowing Regulation: \n\n“Keeping of records in relation to supply and administration of Covid-19 \nvaccination \n\n10B. A person who administers a medicinal product pursuant to \nRegulation 4F (except in the case of epinephrine (adrenaline)) shall within \n7 days of the administration, forward to the Health Service Executive, by \nelectronic means or otherwise, the following particulars in respect of such \nadministration: \n\n(a) \n\n(b) \n\nthe date of administration; \n\nthe name, address, contact number(s), email address(es), \nethnicity, pregnancy status, date of birth and sex of the person to \nwhom the product was administered, to the extent that the \nperson can provide such particulars; \n\n(c) \n\nconfirmation that prior to the administration of the product— \n\n(i) \n\n(ii) \n\nconsent was obtained from the person to whom the \nproduct was administered for its administration, or \n\nif he or she was unable to give such consent, the will and \npreferences of the person was established and the \nadministration was for the benefit of the person; \n\n(d) \n\nthe personal public service number (within the meaning of \nsection 262 of the Social Welfare Consolidation Act 2005) of \nthe person to whom the product was administered, or, where that \nperson does not have, or is unable to give, a personal public \nservice number, other identifying particulars as defined in \nsection 2 of the Health Identifiers Act (No. 15 of 2014); \n\n(e) \n\nthe name, batch number and expiry date of the product; \n\n \n \n\f4 [698] \n\n(f) \n\n(g) \n\nthe name, business address, email and telephone number of the \nperson who supplied and administered the product and the \nnumber of his or her certificate of registration issued by his or \nher professional regulatory body; \n\nthe name, address and telephone number of the general medical \npractitioner (if any) of the person to whom the product was \nadministered to the extent that the person can give such \nparticulars; and \n\n(h) \n\n such other relevant and necessary information as may be \nspecified by the Minister.", "text_norm": "4 principal regulation amended inserting regulation 10a (inserted regulation 6 medicinal product (prescription control supply) (amendment) regulation 2011 (s.i no 525 2011)) following regulation keeping record relation supply administration covid-19 vaccination 10b person administers medicinal product pursuant regulation 4f (except case epinephrine (adrenaline)) shall within 7 day administration forward health service executive electronic mean otherwise following particular respect administration (a) (b) date administration name address contact number(s) email address(es) ethnicity pregnancy status date birth sex person product administered extent person provide particular (c) confirmation prior administration product-- (i) (ii) consent obtained person product administered administration unable give consent preference person established administration benefit person (d) personal public service number (within meaning section 262 social welfare consolidation act 2005) person product administered person unable give personal public service number identifying particular defined section 2 health identifier act (no 15 2014) (e) name batch number expiry date product 4 698 (f) (g) name business address email telephone number person supplied administered product number certificate registration issued professional regulatory body name address telephone number general medical practitioner (if any) person product administered extent person give particular (h) relevant necessary information may specified minister", "start_char": 2986, "end_char": 5233, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-reg-5", "parent_doc_id": "si-2020-0698", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "5. The Eighth Schedule (as substituted by Regulation 4 of the Medicinal", "text_raw": "5. The Eighth Schedule (as substituted by Regulation 4 of the Medicinal \nProducts (Prescription and Control of Supply) (Amendment) (No. 5) \nRegulations 2020 (S.I. No. 401 of 2020)) to the Principal Regulations is \namended by inserting the following entry: \n\nRoute of \nadministration \n\nColumn 3 \nComirnaty is \nadministered \nintramuscularly \nafter dilution as \na course of 2 \ndoses (0.3 mL \neach) at least \n21 days apart \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \nColumn 4 \nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals \n16 years of \nage and older \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministration \n\nColumn 5 \nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand relevant \nnational \nguidelines \n\nColumn 6 \nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister the \nproduct. \n\n“ \n\nMedicinal \nProduct \n\nColumn 1 \nComirnaty \nconcentrate \nfor \ndispersion \nfor injection \nCOVID-19 \nmRNA \nVaccine \n(nucleoside \nmodified) \n\nForm and \npresentation \nof product \nadministered \n\nColumn 2 \nConcentrate \nfor dispersion \nfor injection \n(sterile \nconcentrate) \nin a multidose \nvial and must \nbe diluted \nbefore use. \n\nOne vial (0.45 \nmL) contains \n5 doses of 0.3 \nmL after \ndilution. \n\nOne dose (0.3 \nmL) contains \n30 \nmicrograms of \nCOVID-19 \nmRNA \nVaccine \n(embedded in \n\n \n \n \n \n \n\flipid \nnanoparticles). \n\n[698] 5 \n\n”\n.", "text_norm": "5 eighth schedule (as substituted regulation 4 medicinal product (prescription control supply) (amendment) (no 5) regulation 2020 (s.i no 401 2020)) principal regulation amended inserting following entry route administration column 3 comirnaty administered intramuscularly dilution course 2 dos (0.3 ml each) least 21 day apart indication medicinal product may administered column 4 indicated active immunisation prevent covid-19 caused sars-cov-2 virus individual 16 year age older dosage condition administration place administration column 5 accordance summary product characteristic product administered relevant national guideline column 6 suitable appropriate place regard public convenience need protect health safety public safely administer product medicinal product column 1 comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) form presentation product administered column 2 concentrate dispersion injection (sterile concentrate) multidose vial must diluted use one vial (0.45 ml) contains 5 dos 0.3 ml dilution one dose (0.3 ml) contains 30 microgram covid-19 mrna vaccine (embedded lipid nanoparticles) 698 5", "start_char": 5233, "end_char": 6807, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-reg-6", "parent_doc_id": "si-2020-0698", "section_id": "reg-6", "section_label": "Regulation 6.", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "6. The Principal Regulations are amended by inserting after the Eleventh", "text_raw": "6. The Principal Regulations are amended by inserting after the Eleventh \nSchedule (as substituted by Regulation 4 of the Regulations of 2020) the \nfollowing Schedule: \n\n“TWELFTH SCHEDULE \n\nRegulation 4F \n\nMEDICINAL PRODUCTS WHICH MAY BE SUPPLIED AND \nADMINISTERED BY CERTAIN PERSONS PURSUANT TO \nREGULATION 4F \n\nMedicinal \nProduct \n\nRoute of \nadministration \n\nForm and \npresentation \nof product \nadministered \n\nDosage and \nconditions of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nComirnaty \nconcentrate for \ndispersion for \ninjection \nCOVID-19 \nmRNA Vaccine \n(nucleoside \nmodified) \n\nConcentrate for \ndispersion for \ninjection \n(sterile \nconcentrate) in \na multidose \nvial and must \nbe diluted \nbefore use. \n\nComirnaty is \nadministered \nintramuscularly \nafter dilution as \na course of 2 \ndoses (0.3 mL \neach) at least \n21 days apart \n\nOne vial (0.45 \nmL) contains 5 \ndoses of 0.3 \nmL after \ndilution. \n\nOne dose (0.3 \nmL) contains \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals 16 \nyears of age \nand older \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand relevant \nnational \nguidelines \n\n \n \n \n \n \n \n \n\f6 [698] \n\nEpinephrine \n(adrenaline) \ninjection \n\n30 micrograms \nof COVID-19 \nmRNA \nVaccine \n(embedded in \nlipid \nnanoparticles). \n\nEpinephrine \n(adrenaline) \ninjection \npresented as a \npre-filled \nsyringe or \nampoule \n\nIntramuscular \nor \nsubcutaneous \ninjection \n\nAdults and \nChildren: For \nthe emergency \ntreatment of \nanaphylactic \nshock \n\nIn accordance \nwith the \nsummary of \nproduct \ncharacteristics \nof the product \nadministered \nand relevant \nnational \nguidelines \n\n.” \n\nGIVEN under my Official Seal, \n\n24 December, 2020. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n \n \n \n \n \n \n \n \n \n \n \n\f[698] 7", "text_norm": "6 principal regulation amended inserting eleventh schedule (as substituted regulation 4 regulation 2020) following schedule twelfth schedule regulation 4f medicinal product may supplied administered certain person pursuant regulation 4f medicinal product route administration form presentation product administered dosage condition administration indication medicinal product may administered column 1 column 2 column 3 column 4 column 5 comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) concentrate dispersion injection (sterile concentrate) multidose vial must diluted use comirnaty administered intramuscularly dilution course 2 dos (0.3 ml each) least 21 day apart one vial (0.45 ml) contains 5 dos 0.3 ml dilution one dose (0.3 ml) contains indicated active immunisation prevent covid-19 caused sars-cov-2 virus individual 16 year age older accordance summary product characteristic product administered relevant national guideline 6 698 epinephrine (adrenaline) injection 30 microgram covid-19 mrna vaccine (embedded lipid nanoparticles) epinephrine (adrenaline) injection presented pre-filled syringe ampoule intramuscular subcutaneous injection adult child emergency treatment anaphylactic shock accordance summary product characteristic product administered relevant national guideline  given official seal 24 december 2020 stephen donnelly minister health 698 7", "start_char": 6807, "end_char": 8726, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
{"doc_id": "si-2020-0698-explanatory-note", "parent_doc_id": "si-2020-0698", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 698 of 2020", "title": "1. (1) These Regulations may be cited as the Medicinal Products (Prescription", "year": 2020, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to allow for Covid-19 vaccinations to be \nadministered by pharmacists, nurses and midwives, advanced paramedics, \nparamedics, emergency medical technicians and physiotherapists. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 7) Regulations 2020. \n\n \n \n \n \n \n \n \n \n\f8 [698] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \n52 FAICHE STIABHNA, BAILE ÁTHA CLIATH 2, \nD02 DR67. \n\nTeil: 076 110 6834 \nr-post: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \n52 ST. STEPHEN'S GREEN, DUBLIN 2, \nD02 DR67. \n\nTel: 076 110 6834 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-182) 75. 12/20. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation allow covid-19 vaccination administered pharmacist nurse midwife advanced paramedic paramedic emergency medical technician physiotherapist regulation may cited medicinal product (prescription control supply) (amendment) (no 7) regulation 2020 8 698 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais 52 faiche stiabhna baile atha cliath 2 d02 dr67 teil 076 110 6834 r-post publication opw.ie ------------ dublin published stationery office purchased government publication 52 st stephen green dublin 2 d02 dr67 tel 076 110 6834 e-mail publication opw.ie ------------ eur3.00 (dh-182) 75 12 20 propylon", "start_char": 8726, "end_char": 9773, "source_path": "downloads\\2020\\2020_0697.pdf", "extraction_method": "pdfminer", "checksum": "sha256:4b830f9db7172a4b749e8a30d55fe9d74d8a92f0799bd9e1dac5ea533a3bba0f", "cross_refs": []}
